Global Akeega sales will reach $676 million by 2030, while Talzenna and saruparib reach $618 million and $628 million ...

Akeega – which combines the active ingredients in J&J's PARP inhibitor Zejula (niraparib) and androgen blocker Zytiga ...

The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...

Pfizer Inc. (NYSE:PFE) has unveiled major advances in cancer research at the 2025 ASCO Annual Meeting, spotlighting robust five-year survival results for XTANDI (enzalutamide) combined with ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously (8 to 0) against the risk-benefit profile of talazoparib (Talzenna) combined with enzalutamide (Xtandi) for the treatment of ...

Pfizer's commitment to returning capital to ... lymphoma and encouraging clinical data for Padcev in urothelial cancer. Talzenna also showed positive overall survival data in prostate cancer ...

Pfizer's commitment to returning capital to shareholders is ... approval for Adcetris in large B-cell lymphoma and encouraging clinical data for Padcev in urothelial cancer. Talzenna also showed ...

FDA advisors unanimously voted against expanding Pfizer’s Talzenna to a broader prostate cancer population without HRR mutations, citing flaws in trial design, insufficient statistical power, and ...

An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) for all patients with metastatic ...